Evidence map›Paper›PMID 31823144›Full record

ReviewClinical rheumatology2020

Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review.

Carla Gaggiano, Donato Rigante, Gian Marco Tosi, Antonio Vitale, Bruno Frediani, Salvatore Grosso, Claudia Fabiani, Luca Cantarini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. An Overview of Pediatric Uveitis.Turkish archives of pediatrics · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Juvenile Idiopathic Arthritis Associated Uveitis.Children (Basel, Switzerland) · 2021
    Review
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Carla GaggianoClinical Pediatrics, Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Donato RiganteInstitute of Pediatrics, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
Gian Marco TosiOphthalmology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Antonio VitaleResearch Center of Systemic Autoinflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Bruno FredianiResearch Center of Systemic Autoinflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Salvatore GrossoClinical Pediatrics, Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Claudia FabianiOphthalmology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Luca CantariniResearch Center of Systemic Autoinflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy. cantariniluca@hotmail.com.ORCID http://orcid.org/0000-0002-7352-1275
University of Siena · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic anterior uveitis is the most frequent among extra-articular manifestations of juvenile idiopathic arthritis (JIA) and a relevant cause of ocular morbidity in children. Asymmetric arthritis, early onset disease, female sex, and anti-nuclear antibody (ANA) positivity are counted among risk factors for developing this complication. It usually has insidious onset and asymptomatic chronic-relapsing course, but the persistence of low-grade chronic inflammation can lead to irreversible structural ocular damage and to vision-threatening complications. For such reasons, achieving a complete absence of inflammation through early targeted and aggressive treatments is a primary therapeutic goal in these patients. This review is aimed at summarizing scientific evidence about biologic rescue therapy of JIA-related uveitis in patients who fail to achieve clinical remission, in spite of being treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) and at least one biologic tumor necrosis factor (TNF)-α inhibitor. Interleukin (IL)-6 inhibition appears a promising and safe option for refractory JIA-related uveitis. Abatacept and rituximab proved to be beneficial as well, but their efficacy together with some safety concerns needs to be more extensively evaluated.

Indexed as

Biological TherapyAbataceptAntibodies, Monoclonal, HumanizedArthritis, JuvenileHumansRituximabTreatment FailureTumor Necrosis Factor InhibitorsUveitis, AnteriorAbataceptAntibodies, Monoclonal, HumanizedRituximabtocilizumabTumor Necrosis Factor InhibitorsBiologic therapyChronic anterior uveitisJuvenile idiopathic arthritisRescue treatment

Identifiers

PMID31823144
OpenAlexW2996090672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.